biostudies-literatureUnknown102(10)Mateos MVPrior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) <i>versus</i> placebo-Rd. Patients with relapsed/refractory multiple myeloma received ixazomib-Rd or placebo-Rd. Efficacy and safety were evaluated in subgroups defined according to type (proteasome inhibitor [PI] and immunomodulatory drug) and number (1 <i>vs.</i> 2 or 3) of prior therapies received. Of 722 patients, 503 (70%) had received a prior PI, and 397 (55%) prior lenalidomide/thalidomide; 425 patients had received 1 prior therapy, and 297 received 2 or 3 prior therapies. At a median follow up of ~15 months, PFHaematologica1767-1775https://www.ebi.ac.uk/biostudies/studies/S-EPMC5622861biostudies-literatureImpact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.PMC5622861Mateos MVHansson MBorsaru GDi Bacco AMoreau PJackson SRHamadani MMasszi TGrzasko Nvan de Velde HRichardson PGStoppa AMBerg DLin JPour LViterbo LSandhu IGimsing PfalseImpact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) <i>versus</i> placebo-Rd. Patients with relapsed/refractory multiple myeloma received ixazomib-Rd or placebo-Rd. Efficacy and safety were evaluated in subgroups defined according to type (proteasome inhibitor [PI] and immunomodulatory drug) and number (1 <i>vs.</i> 2 or 3) of prior therapies received. Of 722 patients, 503 (70%) had received a prior PI, and 397 (55%) prior lenalidomide/thalidomide; 425 patients had received 1 prior therapy, and 297 received 2 or 3 prior therapies. At a median follow up of ~15 months, PF2017-01-01T00:00:00Z2017 Oct2025-04-04T14:03:12.965Z2019-07-24T07:12:28ZS-EPMC56228612875156210.3324/haematol.2017.170118